Angiogenex Inc (AGGX) is a leading other business based in the US. It opened the day at $0.18 after a previous close of $0.18. During the day the price has varied from a low of $0.18 to a high of $0.18. The latest price was $0.18 (25 minute delay). Angiogenex is listed on the PINK. All prices are listed in US Dollars.
Since the stock market crash in March caused by coronavirus, Angiogenex's share price has had significant positive movement.
Its last market close was $0.29, which is 55.17% up on its pre-crash value of $0.13 and 187.13% up on the lowest point reached during the March crash when the shares fell as low as $0.101.
If you had bought $1,000 worth of Angiogenex shares at the start of February 2020, those shares would have been worth $1,142.86 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,761.90.
|52-week range||$0.1 - $0.3|
|50-day moving average||$0.1857|
|200-day moving average||$0.1584|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
|1 week (2020-10-15)||-37.93%|
|1 month (2020-09-25)||0.18|
|3 months (2020-07-24)||50.00%|
|6 months (2020-04-24)||78.22%|
|1 year (2019-10-24)||73.08%|
|Gross profit TTM||$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
TTM: trailing 12 months
We're not expecting Angiogenex to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
AngioGenex, Inc. (AngioGenex) is a development-stage company. The Company is a biopharmaceutical company focused on the manufacturing of products for the treatment, diagnosis and prognosis of cancer. The Company focuses to develop orally active anti-cancer drugs that act by modulating the action of the inhibitor of differentiation (Id) proteins, measurement of Id proteins in tumors and blood to create products for the diagnosis and prognosis of cancer and generating proof-of-concept data in relevant preclinical models to establish that modulation of Id genes and proteins is useful to treat non-oncologic diseases in which a surplus or deficit in the growth of blood vessels is an important part of the underlying pathology.
Everything we know about the Virpax Pharmaceuticals IPO, plus information on how to buy it.
Everything we know about the Vivos Therapeutics IPO, plus information on how to buy it.
Everything we know about the Kiromic Biopharma IPO, plus information on how to buy it.
Everything we know about the Codiak BioSciences IPO, plus information on how to buy it.
Everything we know about the Triller IPO, plus information on how to buy it.
Everything we know about the Eastern Bank IPO, plus information on how to buy it.
Everything we know about the Wish IPO, plus information on how to buy it.
Everything we know about the MINISO Group Holding Limited IPO, plus information on how to buy it.
Everything we know about the Playboy IPO, plus information on how to buy it.
Everything we know about the iHuman IPO, plus information on how to buy it.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.